The present invention inter alia relates to an enhanced chimeric CD8 Co-receptor, wherein the CD8 Co-receptor comprises a polypeptide including at least one functional polypeptide domain or a functional polypeptide motif of a CD8 Co-receptor, and wherein said polypeptide further comprises at least one CD8-derived polypeptide region including a functional polypeptide domain or a functional polypeptide motif of a wildtype human CD8 Co-receptor.The enhanced chimeric CD8 Co-receptor further comprises at least one cytoplasmic polypeptide domain or cytoplasmic polypeptide motif of a tumor necrosis factor receptor superfamily protein, a immunoglobulin superfamily (IgSF) protein, and/or an ITAM-associated receptor. The present invention also relates to a nucleic acid encoding the enhanced chimeric CD8 Co-receptor, a vector comprising the nuclear acid encoding for the enhanced chimeric human CD8 Co-receptor, as well as to isolated T-cells being transduced, transformed or transfected with the nucleic acid or the with the vector, and to isolated T-cells being transduced, transformed or transfected to express the enhanced chimeric CD8 Co-receptor as well as to engineered T-cells expressing the chimeric CD8 Co-receptor. The invention further relates to a kit for preparing the isolated T-cells of the present invention, as well as to a pharmaceutical composition comprising the T-cells. The invention also relates to a method for preparing a T-cell for immunotherapy, and to a method for treating a patient having a disease comprising administering the pharmaceutical composition.
- 출원번호 : EP2024/071709
- 출원인 : T-KNIFE GMBH
- 특허번호 :
- IPC : C07K-014/73(2006.01);C07K-014/705(2006.01);A61K-038/00(2006.01);